- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
An Army-sponsored phase III clinical trial (RV144) involving more than 16,000 adult volunteers in Thailand showed that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.
RV217: A multi-site research study on acute HIV infections
RV254: An early HIV infection study in Thailand
RV262: Phase I study to evaluate a combination DNA prime/MVA vector boost vaccine regimen
RV305: Immunogenicity study evaluating extended boosting regimens using the same vaccine components used in RV144
RV329: African Cohort Study
New findings published this week in the Journal of Infectious Diseases found HIV-1 viral load and subtype to be the primary predictors of disease progression in rural Uganda.
The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa.
MHRP and collaborators will present at the 2014 HIV Research for Prevention Conference (R4P) in Cape Town, South Africa, October 26 - 31st.
COL Jerome Kim will transition in 2015 to become the Director-General of the International Vaccine Institute (IVI), a Seoul-based non-profit devoted to research in vaccine development and delivery.
The Role of Research Nurses in HIV Research
Nurses play an integral role on the research team of HIV studies and vaccine clinical trials. Read more about two hard-working nurses who are helping MHRP in the quest to find an end to AIDS.
Video: Early HIV Infection Study Offers Insight Into the Initial Stages of HIV Infection
MHRP researchers and Thai collaborators are leading the way in acute infection studies. One study, called RV254/SEARCH 010 is providing knowledge about the earliest HIV events that may provide clues to developing an effective HIV vaccine or even help identify ways to achieve a functional cure.